



www.MedChemExpress.com

Inhibitors, Agonists, Screening Libraries

Factor Xa

Fxa


Factor Xa is the activated form of the coagulation factor thrombokinase, known eponymously as Stuart-Prower factor. Factor X is an enzyme, a serine endopeptidase, which plays a key role at several stages of the coagulation system. Factor X is synthesized in the liver. Factor Xa has emerged as an attractive target for novel anticoagulants for its key position in the coagulation cascade and its limited roles outside of coagulation. The most commonly used anticoagulants in clinical practice, warfarin and the heparin series of anticoagulants and fondaparinux, act to inhibit the action of Factor Xa in various degrees. As a result, the past decade has witnessed an explosion of research into small-molecule, oral, direct Factor Xa inhibitors, and several are now in clinical development.

Factor Xa Inhibitors

5-R-Rivaroxaban

Cat. No.: HY-76948

5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct **Factor Xa (FXa)** inhibitor, achieving a strong gain in anti-FXa potency (IC_{50} 0.7 nM; K_i 0.4 nM).




Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apixaban

(BMS-562247-01)

Cat. No.: HY-50667

Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of **Factor Xa** with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.




Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Betrixaban

(PRT054021)

Cat. No.: HY-10268

Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious **factor Xa (fXa)** inhibitor with IC_{50} of 1.5 nM.




Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Edoxaban

(DU-176)

Cat. No.: HY-10264

Edoxaban (DU-176) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_i s of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.




Purity: 99.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Edoxaban tosylate

(DU-176b)

Cat. No.: HY-10264A

Edoxaban tosylate (DU-176b) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_i s of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively. Edoxaban tosylate is an anticoagulant agent and can be used for stroke prevention.




Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Edoxaban tosylate monohydrate

(DU-176b monohydrate)

Cat. No.: HY-10264B

Edoxaban tosylate monohydrate (DU-176b monohydrate) is a selective, potent and orally active **factor Xa (FXa)** inhibitor with K_i s of 0.561 nM and 2.98 nM for **free FXa** and **prothrombinase**, respectively.




Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fondaparinux sodium

(Fondaparinux sodium; SR-90107A)

Cat. No.: HY-B0597

Fondaparinux sodium is an antithrombin-dependent **factor Xa** inhibitor.




Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Gabexate mesylate

(FOY)

Cat. No.: HY-B0385

Gabexate mesylate is a Factor X inhibitor; serine protease inhibitor.




Purity: 98.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 100 mg

Heparin sodium salt (MW 15kDa)

(Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa))

Cat. No.: HY-17567C

Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa.




Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

Otamixaban

(FXV673)

Cat. No.: HY-70035

Otamixaban (FXV673) is a potent ($K_i = 0.5$ nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.




Purity: 98.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 100 mg

Rivaroxaban
(BAY 59-7939)

Cat. No.: HY-50903

Rivaroxaban (BAY 59-7939) is a highly potentselective and direct **Factor Xa (FXa)** inhibitor, achieving a strong gain in anti-FXa potency (IC_{50} 0.7 nM; K_i 0.4 nM).



Purity: 99.93%


Clinical Data: Launched

Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RWJ-445167
(3DP-10017)

Cat. No.: HY-19373

RWJ-445167 (3DP-10017) is a dual inhibitor of **thrombin** and **factor Xa** with K_i of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.



Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg